Prostate Cancer
Conditions
Brief summary
This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.
Interventions
None listed
Sponsors
NYU Langone Health
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy * Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) will be counseled regarding treatment options. Those selecting focal Cryo prostate ablation will then be offered inclusion into this data collection.
Exclusion criteria
* Men that are not diagnosed with prostate cancer. * Men that are diagnosed with clinically localized prostate cancer, but select other treatment options as their desired treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Complications | Up to Year 15 | — |
| PSA-Progression Free Survival | Up to Year 15 | Length of time following cryotherapy for ablation treatment of prostate cancer that a patient lives without their prostate-specific antigen (PSA) levels rising significantly enough to indicate disease recurrence, or without dying from any cause. |
Countries
United States
Contacts
CONTACTMajlinda Tafa
CONTACTJames Wysock, MD
PRINCIPAL_INVESTIGATORJames Wysock, MD
NYU Langone Health
Outcome results
None listed